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  The aim of the study was to examine the function of platelets in children and adolescents with 
Schönlein-Henoch Syndrome (SHS) presenting normal platelet count, and epidemiologic data. The most 
frequent SHS localization was the skin and joints. The most consistent defect in platelet aggregation was a 
block of the release of endogenous ADP when ADP was used as induction agent. In conclusion, our 
epidemiological data differ slightly from those observed by other authors. However, we have shown that 
increased tendency toward bleeding in SHS might be caused by function disturbances of platelets. 




Svrha istraživanja bila je ispitati funkcionalnost trombocita u djece i adolescenata koji su bolovali od 
Schönlein-Henoch sindroma (SHS) u sklopu kojega se mogu pojaviti pojačana krvarenja, uz normalan broj 
trombocita, te prikazati epidemiološke podatke za istu populaciju. Najčešća mjesta manifestacije bolesti bila 
su koža i zglobovi. Bolest je bila najčešća u djece starosti između 7 i 20 godina, češća u djevojčica nego u 
dječaka. Najčešći poremećaj fiziološke aktivnosti trombocita bio je blokada otpuštanja endogenog ADP-a u 
slučaju kada je kao indukcijski agens bio upotrijebljen ADP. Štoviše, u 6 je pacijenata pokazana 
istovremena dezagregacija trombocita. Očito je da je pojačano krvarenje u sklopu SHS uzrokovano 
smanjenom funkcionalnom sposobnošću trombocita. 










Schönlein-Henoch Syndrome (SHS) in children    
is an acquired disease caused by abnormal immuno-
logical response to different antigens such as 
infectious agents, drugs, food, etc. The abnormality of 
the immunological reaction is characterized by the 
deposition of IgA1 containing immune complexes 
(IC) within small vessel walls that cause in-
flammation of the endothelium and thickening of a 
vessel’s walls due to edema, fibrinoid necrosis and 
endothelial cell expansion.1 
Clinical and pathological changes include non-
thrombocytopenic purpura, skin changes, joint 
lesions, abdominal pain with gastrointestinal bleeding 
and renal involvement. Approximately 2/3 of patients 
have upper respiratory tract symptoms before the 
onset of the disease, 20% show evidence of previous 
streptococcus infection, previous consummation of 
certain drugs or food (milk, eggs, chocolate), insect 
bites, exposure to chemical poisoning or proof of 
previous vaccination.2,3 1 
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The disease is more frequent in boys. Around 75% 
of children are of pre-school age (2-8 years).1,4-6 
Children with SHS usually recover spontaneously 
but the disease, especially in the first year after the 
first attack, may recur.  
There are no distinctive laboratory abnormalities 
associated with SHS. Clinical purpuric bruises and 
gastrointestinal bleeding may suggest coagulation 
disturbance.7,8 In addition, some other authors 
demonstrated the presence of abnormally large von 
Willebrand multimers in platelets and the endothelial 
cell9, while other authors described the decrease        
of plasma coagulation factor VIII (F VIII).10,11 
Additionally, acquired factor XIII deficiency has been 
described in SHS.12 Petersen and co-workers have 
found platelet-associated Ig (PAIg) in 75% of 
children with SHS and indicate its close relationship 
with autoimmune disease13. In the light of the above 
findings, and the fact that there are no data about 
(except in Coppo R. report) 11 the function of platelets 
in SHS-patients, not even in large epidemiologic 
retrospective studies done so far,1,4-6 the aim of our 
study was:  
1) to present epidemiologic data (age, gender, 
season of SHS occurrence) and clinical features (the 
incidence, nature of SHS, localization of the disease) 
of 153 children suffering from SHS, 
2)  to examine the qualitative function of 
platelets in SHS-children presenting normal platelet 
count.  
 
Patients and methods 
 
This retrospective study included 153 children and 
adolescents of European Caucasian origin with SHS 
hospitalized at the Pediatric Clinic of Split Clinical 
Hospital Center in the period from February 1987 to 
May 2002. According to the ACR (American College 
of Rheumatology) recommendations, all patients 
expressed at least two criteria for SHS. There were 82 
girls (2 of them, 1 to 6 years old, and 80 in ages from 
7 to 20 years), and 71 boys (five in ages from 1 to 6 
years, and 66 of ages between 7 and 20 years). The 
analysis of data of the selected patients was 
performed by reviewing the medical charts. These 
data included: the incidence and nature of SHS, 
localization of the disease, other symptoms, induced 
platelet aggregation analysis, and frequency of 
corticosteroid treatment. No patient took anti 
aggregation drugs or a drug that could disturb 
platelets function. The epidemiological data collected 
were age, gender and season of SHS occurrence.  
Platelet function was analyzed in 44 patients in 
order to determine the abnormalities in platelet 
aggregation. The analysis was done by standard Born 
method on the Chrono-log machine, model 330 
platelet aggregometer (Chrono-Log Corp., Havertown, 
PA, USA)14,15 after platelets aggregation induction by 
ADP (3 µM) and adrenaline (1.5 µM). Normal 
reference intervals in children are: ADP 68.6 – 92.3% 
and adrenaline 66.7 – 95.0%.16 
This study received the approval of the Ethics 




The annual number of hospitalized children with 
SHS varied from 3 to 19 in a period from 1987 - 
2002. Most of the children were hospitalized in the 
war years 1993 and 1994 (19 and 15) due to refugees 
from other parts of Croatia and from Bosnia and 
Herzegovina (Table 1). 
 
Table 1. Number of hospitalized children with SHS  
during the period from 1987 to 2002  
Tablica 1. Broj hospitalizirane djece s SHS u 
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Total number of children = 153 
Sveukupan broj djece = 153 
 
The largest number of hospitalized children 
regarding to the month of disease onset was in 
October (15.7%) and in January (13.1%). It is highly 
evident that the greater number of hospitalized 
children in autumn and in winter was due to upper 
respiratory tract infection that is considered the most 
frequent trigger of this disease (Table 2). The most 
frequent localization of SHS was the skin (99.3%). 
Skin changes presented as maculopapular rash were 
usually on the legs, buttocks, hands and chest. The 
next localization was the joints (84.3%) in the form of 
swelling, tenderness, pain and limited movement. 
Abdominal pain, nausea, vomiting and bloody stool 
appeared in 38 cases (24.8%). In all children SHS 
was localized to the skin and joints, and in only some 
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of them to the abdomen and kidney. In fifty-one 
children (33.3%) SHS affected the kidneys, while 
four of them (2.6%) had nephritis.  
 
Table 2. Month-by-month frequency of SHS onset in 
children  
Tablica 2. Mjesečna učestalost nastupa SHS kod 
djece  
 
Month of the 








Siječanj 20 13.1 
February 
Veljača 13  8.5 
March 
Ožujak  12  7.8 
April 
Travanj  14  9.2 
May 
Svibanj  8  5.2 
June 
Lipanj  9  5.9 
July 
Srpanj 6  3.9 
August 
Kolovoz  7  4.6 
September 
Rujan  15  9.8 
October 
Listopad  24 15.7 
November 
Studeni  12  7.8 
December 
Prosinac  13  8.5 
 
One child had CNS symptoms (Table 3). Most of 
the girls with SHS were of school age (7-20 years) 
(97.6%). Their most frequent SHS localization was 
the skin (98.7%), joints (70%), kidneys (33.8%), and 
abdomen (18.8%). The same frequency of SHS 
localization was also observed in two girls 1 to 6 
years of age (Table 3). 
Most of the boys with SHS were also of school 
age (7-20 years old) (93%). Their most frequent SHS 
localizations were the skin (100%), joints (100%), 
abdomen (33%) and kidneys (31.8%). However, one 
boy also had central nervous system (CNS) 
symptoms. In younger boys both, skin and joints SHS 
related problems were evident. Invagination was the 
first symptom of SHS in one boy. Purpuric skin rash 
become evident the day after invagination and its 
surgical correction.  
The platelet function was analyzed to determine 
abnormalities in the platelet aggregation. The first-
phase of platelet aggregation involves direct platelet 
aggregation induced by ADP or adrenaline. The 
second-phase aggregation involves platelet endo-
genous ADP release. Forty-two children with SHS 
and normal platelet count were tested for platelet 
aggregation (Table 4). The first-phase of platelet 
aggregation induced with ADP was normal in 7 
(16.7%), slightly decreased (to 50-60%) in 3 (7.1%) 
and increased in 32 patients (76.2%). The second-
phase of platelet aggregation stimulated by ADP was 
normal in 6 (14.3%), slightly decreased in 4 (9.5%), 
increased in 12 patients (28.6%), while 20 (47.6%) 
patients had a block of endogenous ADP release. In 6 
out of these 20 patients, block of endogenous ADP 
release and disaggregation appeared simultaneously.  
Additionally, when platelet aggregation was 
induced by adrenaline, the first-phase aggregation 
was normal in 22 patients (52.4%), slightly decreased 
in 6 (14.2%) and increased in 14 patients (33.3%).  
Table 3. Frequency of SHS localization 
Tablica 3. Učestalost SHS lokalizacije 
SHS – Localization by organs 
SHS – Lokalizacija prema organima 
 Girls / Djevojčice Boys / Dječaci  










Number of girls/boys 
Broj djevojčica/dječaka 2 (2.4%) 80 (97.6%) 5 (7%) 66 (93.0%) 153  
Skin / Koža  2 (100.0%) 79 (98.7%) 5 (100%) 66 (100.0%) 152 (99.30%) 
Joints / Zglobovi  2 (100.0%) 56 (70.0%) 5 (100%) 66 (100.0%) 129 (84.30%) 
Abdomen / Trbuh  1 (50.0%) 15 (18.8%) 0  22 (33.0%) 38 (24.80%) 
Kidney / Bubreg  1 (50.0%) 27 (33.8%) 2 (40%) 21 (31.8%) 51 (33.30%) 
CNS / CNS 0  0  0  1 (1.5%) 1 (0.65%) 
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Table 4. Induced platelet aggregation in patients with SHS 
Tablica 4. Indukcijska poremetnja agregacije kod pacijenata s SHS 
 
 
 The second-phase aggregation was normal in 10 
patients (21.4%), slightly decreased in 8 (19.0%), 
increased in 16 patients (38.0%), while 8 patients 
(19.0%) demonstrated complete block of endogenous 
ADP release. There was no correlation between the 
type of platelet aggregation and SHS localization.  
According to our results, the most consistent 
defect in the examined aggregograms of the 42 
children with SHS was a block of the release of 
endogenous ADP when ADP was used as an 
induction agent. Of 153 children, 88 (57.51%) were 
successfully treated with methylprednisolone because 
of intensive skin reaction, kidney, gastrointestinal and 




The Schönlein-Henoch Syndrome is a rare disease 
with an incidence rate in children of about 20 per 
100,000 children per year.17 It affects pre-school 
children more often than school children, boys more 
than girls. It is the most common vasculitis in 
childhood. 18 The reason for SHS occurrence is most 
often due to upper respiratory tract infections.  
According to the ACR criteria for classification of 
SHS, the overall yearly incidence rate of SHS in the 
Republic of Croatia are 30-32/100,000 children aging 
up to 14 years, and are more frequent in boys. Our 
epidemiologic study was conducted in Split Clinical 
Hospital which is the main hospital in Dalmatia, the 
Adriatic coast sub-region of Croatia. The recorded 
incidence rate of SHS in our cohort study group was 
lower than for the whole country (ranging from 3-
15/100.000 children, with the exception of two war 
years). This discrepancy could be ascribed to a lower 
incidence of respiratory tract infections in this region 
due to weather and environmental factors. In 
particular, the average yearly temperature in this 
region is much higher than in the rest of the country 
and the overall cleanness of the air in Dalmatia is 
much better due to the specific winds that blow there 
and to the beneficial activity of the sea salinity in the 
air. In addition, we have also noted a slight decline of 
SHS occurrence over the recent years. The 
discrepancies in the SHS incidence rate have been 
shown by other authors as well, supporting the idea 
that, in addition to yet unknown genetic factors, 
environmental factors may play a role in the 
pathogenesis of SHS.6,18-20 Although it is accepted 
that SHS is a disease of pre-school children more 
often present in boys, we were not able to confirm 
these statements. In our cohort study group, the 
disease was slightly more common in girls (53.6%) 
than in boys (46.4%), and occurred most frequently 
between ages 7 and 20 when children and adolescents 
attending school are more frequently exposed to 
respiratory infections. The same gender prevalence of 
the disease was also found by other authors4,21. 
In our patient cohort, SHS was more commonly 
diagnosed during the autumn and winter season as 
compared to the summer season that is in agreement 
with most previous epidemiologic studies done so far. 
The most frequent trigger of the disease was due to 
upper respiratory tract infection. However, two 
different seasonal peaks of SHS were observed by 
Doležalova22 (November and March), and, surpri-
singly, only one in June, by Coppo and coworkers.11 













Aggregation – phase 
Faza agregacije 
Number of patients (%) / Broj pacijenata (%) 
I 7 (16.7) 3 (7.1) 32 (76.2) 
II 6 (14.3) 4 (9.5) 12 (28.6) 
- block of endogenous ADP release 






- with disaggregation 
- sa disagregacijom 6 (14.3) 
  
I 22 (52.4) 6 ( 14.2) 14 (33.3) 
II 10 (21.4) 8 (19.0) 16 (38.0) 
 
Adrenalin 
- block of endogenous ADP release 
- blokada otpuštanja endogenog ADP-a 8 (19.0) 
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Our data about SHS localization do not differ 
significantly from the data described by other 
authors.4-6 Skin (99%) – joints (84%) SHS type was 
the most frequent. Kidney involvement manifested 
very often as microscopic hematuria and/or albu-
minuria (33.3%) while glomerulonephritis appeared 
in four children (2.6%). Most of the kidney 
complications affected children aging between 7 and 
9 years. SHS can be complicated by encephalo-
pathy23. One child from our sample had CNS 
complications resulting in disorientation, sleepiness 
and staggering. Such complications are rarely 
described.24,25  
SHS can also be associated with lungs,26 liver,27 
genital28 and pancreas29 complication, which we did 
not encounter in our study group. 
One clinical symptom of SHS in most patients is a 
mild or increased bleeding tendency. The number of 
platelets in these patients was normal, while the 
platelet function can be decreased.  
The platelet function may be disturbed in a wide 
variety of disorders such as myeloproliferative and 
immunologic diseases. Platelet in patients with 
immune thrombocytopenia (ITP) in remission may 
have an abnormal function, such as aggregation and 
adhesion defects,30,31 In 1961, Gaarder and 
coworkers32 showed that ADP stimulates platelet 
aggregation (PA). ADP is a physiological agent in 
thrombogenesis. It also behaves as an agonist of 
blood PA, although its mechanism of action is not 
well understood. At low concentrations ADP 
produces only platelet shape changes14 and at higher 
concentrations it causes reversible aggregation.33 
The most consistent defect of platelet function in 
our study was a block of the release of endogenous 
ADP when ADP was used as an induction agent. 
Moreover, six of these patients demonstrated conco-
mitant disaggregation. Only 19% of patients demon-
strated complete block of endogenous ADP release 
when adrenaline was used as an induction agent.  
The exact mechanisms of abnormal platelets 
aggregation not only in SHS but also in other 
disorders connected with bleeding problems are not 
known. They might include a variety of causes. For 
instance, most acquired disorders of platelet function 
result from abnormalities of platelet granules and 
membrane proteins. However, while Weiss showed 
that platelet α- and dense granule content were 
reduced in two patients with systemic lupus 
erythematosus and in one with ITP,34 increased 
platelet α-granule secretion and an acquired storage 
pool defect of dense granules were observed in 
myeloproliferative disorders.35-37 
Furthermore, platelet dysfunction in patients with 
SHS may suggest that immune mediated disorder can 
affect platelets resulting in acquired disease of ADP 
release.  
In conclusion, we have shown that an increased 
tendency toward bleeding in SHS might be caused by 
qualitative function of platelets disturbance. 
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